3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Neoplasms
13
Carcinoma, Non-Small-Cell Lung
8
Breast Neoplasms
7
Neoplasm Metastasis
6
Melanoma
5
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Leukemia, Myeloid, Acute
3
Solid Tumor
2
Recurrence
2
Prostatic Neoplasms
2
Lung Neoplasms
2
Gastrointestinal Stromal Tumors
2
Colorectal Neoplasms
2
Carcinoma
2
Advanced Solid Tumor
2
Advanced Malignancies
2
cMET-dysregulated Advanced Solid Tumors
1
Urothelial Cancer
1
Thyroid Neoplasms
1
Synovitis, Pigmented Villonodular
1
Solid Tumours
1
Solid Tumour
1
Solid Tumors, KRAS Mutation
1
Solid Tumors
1
Solid Tumor, Adult
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Prostate Cancer Patients
1
Interventions
Doxorubicin
5
Dacarbazine
5
Trabectedin
3
belinostat
2
PTC596
2
toripalimab
1
soblidotin
1
rucaparib
1
ridaforolimus
1
reolysin
1
pembrolizumab
1
pazopanib
1
olaratumab
1
futibatinib
1
cixutumumab
1
cemiplimab
1
anlotinib
1
Tablets
1
TTI-621
1
Rosuvastatin Calcium
1
PM 01183
1
Midazolam
1
Injections
1
Imatinib Mesylate
1
Ifosfamide
1
Fluorouracil
1
Erlotinib Hydrochloride
1
Docetaxel
1
Digoxin
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leiomyosarcoma
×
Midazolam
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled